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The nuclear receptor ligand-binding domain (LBD) is a highly dynamic entity. The FXR 
LBD shows multiple low-energy conformational states of the activation function-2 (AF-2) 
coregulator binding surface upon ligand binding, indicating the complexity of FXR 
activation. However, it is unknown how ligand binding leads to different conformational 
states within the AF-2 region centered on helix 12 (H-12) of the LBD. Here we observe 
the conformation of the coregulator binding surface (H-12 specifically) of FXR upon 
ligand binding in solution using fluorine-19 (19F) nuclear magnetic resonance (NMR) and 
simulations of this surface using molecular dynamics.  Fluorescence anisotropy of 
fluorescein-labeled coregulator peptides reveals a correlation between structural 
conformations of the coregulator binding surface and the function of FXR. While the 
coregulator surface of apo FXR and partial-agonist bound FXR exchanges between 
multiple low energy conformations, full-agonist bound FXR is restricted to few 
conformations, which favor coactivator binding. Furthermore, we find that two ligands that 
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Farnesoid X receptor (FXR) is a ligand-activated transcription factor,1 found mainly in the 
liver and kidney2. FXR maintains the homeostasis of bile acids, vital for metabolic 
regulation and liver protection by regulating bile acids3. Like other nuclear receptors (NR) 
superfamily members, FXR recruits coregulators upon ligand binding, thereby changing 
the expression level of genes involved in bile acid, glucose, and lipid metabolism. Because 
it regulates bile acids in the liver, FXR is a potential drug target for treating several liver-
related disorders, including nonalcoholic steatohepatitis (NASH) and primary biliary 
cholangitis (PBC), and diabetes4,5.  
 
Partial FXR activation is a promising strategy to target liver disorders and to reduce 
mechanism-based side effects. Partial Nuclear Receptor agonists have lower gene 
activation efficacy than full agonists, and promising results have been seen for partial FXR 
agonists in pre-clinical and phase 1 clinical data6.  
 
The ligand-binding mechanism to the ligand-binding domain (LBD) of an NR and the 
structural changes that occur upon binding that lead to gene expression changes differ 
among NRs7. Therefore, the structural changes that lead to FXR activation are unclear.  
 
NR structure is highly conserved, consisting of a set of standard functional domains. A 
highly variable N-terminal ligand-independent activation domain followed by a highly 
2 
conserved DNA-binding domain (DBD) and a ligand-binding domain (LBD) that consists 
of twelve alpha-helices (H-1 to H-12). A flexible hinge region separates LBD from DBD.  
There are two coregulator binding activation function (AF) sites; AF-1 is located on N-
terminus while AF-2 is on the C-terminus (H-12 of LBD). For several nuclear receptors, 
the AF-2 site is crucial for NR activation by small-molecule ligands. Ligand binding 
changes the conformation of the AF-2 helix, providing a surface for coactivator binding8. 
 
Previous studies have suggested a mousetrap model for NR activation in which H-12 is 
positioned away from the core LBD in the apo state, which switches to a more compact 
structure with H-12 contacting the core LBD upon ligand binding9. Later studies have 
revised this mouse trap model of activation. They suggest that H-12 is dynamic and 
possibly non-helical in the apostate, and H-12 is only formed and stabilized upon agonist 
binding. This model suggests that more than a single active conformation of NR-LBDs 
exists10. Studies have already shown differential effects of FXR agonists on FXR regulated 
gene expression, implying that FXR activation is more complex than the mechanism 
described by the mousetrap model11. Different FXR ligands lead to different coactivator 
recruitment profiles12,13. This phenomenon has also been reported for other NRs, including 
PPARγ14. 
 
To better understand FXR activation and observe different conformational states of H-12 
upon binding of FXR ligands, we have used ligands that have been previously 
characterized in cells as agonists and antagonists for structural investigation. We employ 
19F-NMR and molecular dynamics (MD) simulation to determine how ligand binding 
3 
changes the conformation of the FXR LBD. Our study indicates that a full agonist induces 
different conformational states than two partial agonists, which induce different FXR states 
from each other. However, one of them induces similar states as that of apo. Thus, this 





1. Nuclear Receptor (NR) 
 
Hydrophobic messenger molecules such as steroid hormones, retinoids, and free fatty acids 
control many aspects of developmental, reproductive, and metabolic processes in 
eukaryotes15. These molecules require carrier proteins (globulins) for their distribution; 
they can enter the plasma membrane and are captured by intracellular receptors. These 
“nuclear receptors” (NRs) are DNA-binding proteins that act as transcription factors16. 
Thus, the NR are ligand-activated transcriptional factors that principally act by binding 
DNA and controlling transcription. 
 
1.1 NR structure 
NR superfamily members share a standard modular domain structure, consisting of five 
domains: A-E (Fig. 1). Each of these domains plays a crucial role in NR biology. 
 
Fig. 1: Domain structure of NRs. [Figure adapted from Weikum et al., 2018]17 
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A/B: N-terminal domain (NTD): The NTD is a highly disordered domain with little 
sequence conservation and significant size differences among NRs. The NTD contains the 
activation function-1 (AF-1) region, which interacts with coregulators in a cell in a 
promoter-specific manner and, in general, is disordered. Variability in this region produces 
multiple isoforms via alternative splicing and is a target for many post-translational 
modifications18. 
 
C: DNA binding domain (DBD): The DBD is the most conserved region among all 
members of the NR superfamily. DBD consists of two subdomains. Each consists of four 
cysteine residues that coordinate a zinc ion to form a canonical DNA-binding zinc finger 
motif17,19 (Fig. 2). 
 
 
Fig. 2: NR DNA binding domain (a) NR DBD indicating significant motifs (b) folded DBD 
indicating essential regions. [Figure adapted from Weikum et al., 2018]17 
 
D: Hinge region:  A short and flexible region that separates the DBD and LBD. The hinge 
region has low sequence and size conservation among NRs. 
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E: Ligand Binding domain (LBD): The LBD is comprised of approximately 12 alpha-
helices, which form three antiparallel helical layers described as an alpha-helical sandwich. 
The LBD binds ligands in the ligand-binding pocket (LBP) and contains the primary 
surfaces involved in homodimerization or heterodimerization with other nuclear receptors. 
The LBP is primarily a hydrophobic internal pocket surrounded by helices (Fig. 3). The 
LBP is variable among NRs compared to other parts of LBD, which allows it to recognize 
a diverse group of ligands. 
 
The LBD also contains the AF-2 region consisting of helices 3, 4, and 12. The binding of 
ligand to LBP changes the conformation of the AF-2 region to facilitate interaction with 
different coregulator proteins (Fig. 3). 
 
Fig. 3: Cartoon representation of structurally conserved NR LBD and its various regions. [Figure 
adapted from Weikum et al., 2018]17 
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1.2 NR structure-function relation 
NR function is determined by two globular structural domains: a moderately conserved C-
terminal LBD and a highly conserved and centrally located DBD. The LBD serves essential 
functions as it contains an LBP specific for its cognate hormone or ligand and an AF-2 
region important for recruiting various coregulator proteins. 
The DBD docks the NR to the hexanucleotide response elements located within nuclear 
receptor-regulated promoters, leading to various transcriptional outputs. After DNA 
binding NR recruits coregulators which then interact with chromatin-remodeling proteins 
and control the general transcriptional machinery15,20. 
 
1.3 NR classification 
NRs are classified into four subtypes 17 
Type 1 NRs: These steroid receptors are activated by cholesterol-derived steroidal 
hormones. Type I NRs are found in the cytoplasm bound to chaperone proteins, but upon 
binding of ligand undergo nuclear translocation where they generally bind as homodimers 
to DNA response elements (Fig. 4a). An example of a type 1 NR is the estrogen receptor 
(ER). 
 
Type 2 NRs: These NRs are generally retained in the nucleus and swap corepressor to 
coactivator upon ligand binding. They generally form heterodimers with RXR (retinoid X 
receptor, a common heterodimeric partner of many NRs) when bound to DNA response 
elements (Fig. 4b). An example of a type 2 NR is the retinoic acid receptor (RAR). 
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Type 3 NRs:  These NRs have a mechanism of action similar to type 2 NRs but form 
homodimers when bound to DNA response elements (Fig. 4c). An example of a type 3 NR 
is the Vitamin D3 receptor (VDR) 
 
Type 4 NRs: These NRs have a mechanism of action similar to type 2 NRs but bind to DNA 
response elements as a monomer (Fig. 4d). An example of a type 4 NR is Liver receptor 
homolog 1 (LRH-1). 
 
 
Fig. 4: NRs signaling mechanism. (a) type 1 (b) type 2 (c) type 3 (d) type 4. The color scheme is 
as follows, NR (blue), chaperone protein (red), RXR (green), coactivator (purple), and corepressor 
(orange). [Figure adapted from Weikum et al., 2018] 17 
 
8 
1.4 NRs as a drug target 
NRs regulate many physiological processes such as metabolism, inflammation, 
reproduction, and development. NR activities are tightly controlled as they are responsible 
for regulating many genes21,22. Therefore, any disorder in NR activity can lead to numerous 
diseases such as diabetes, cancer, and chronic inflammation23,24. Structural and genomic 
studies of NRs have helped develop synthetic ligands targeting these receptors. However, 
since NRs regulate many genes and many ligands are not specific to a given NR, ligand 
binding often leads to both desired and undesired effects. A better understanding of the NR 
regulation mechanism could help identify ligands that affect only a subset of all NR-
regulated genes instead of all the genes under the control of a given NR. 
 
 
2. Farnesoid X Receptor (FXR) 
 
Farnesoid X receptor (FXR) is a ligand-activated transcription factor of the nuclear 
receptor type 2, superfamily1. Bile acids are physiological ligands for FXR; hence FXR is 
also known as the bile acid receptor. 
 
Bile acids are essential for the solubilization and transport of dietary lipids and a significant 
product of the enzymatic conversion of cholesterol. Bile acid bound FXR represses 
transcription of the gene encoding cholesterol 7α-hydroxylase, the rate-limiting enzyme in 
bile acid synthesis, and activates the gene encoding intestinal bile acid-binding protein, a 
candidate BA transporter, indicating a mechanism by which BA transcriptionally regulates 
its biosynthesis and enterohepatic transport25.    
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FXR plays a crucial role in bile acid homeostasis by regulating genes involved in bile acid 
synthesis, conjugation, and enterohepatic circulation. In addition, FXR as a metabolic 
regulator also plays an essential role in cholesterol, lipid, and glucose metabolism.  
 
2.1 FXR expression 
 There are two FXR genes (FXRα (NR1H4) and FXRβ (NR1H5)) in mammals26. FXRβ is 
a functional receptor in rodents but is a pseudogene in humans and primates27. The 
functional role of FXRβ is not well known. A single FXRα gene can encode FXRα1 or α2 
and FXRα3 or α4 isoforms, but the physiological role of this diversity is not clearly 
understood28. Alternate splicing gives rise to the multiple isoforms which differ at the AF-
1 domain, FXRα3 and FXRα4 possess an extended N-terminal AF-1 domain compared to 
FXRα1 and FXRα2 (Fig. 5b). These four isoforms are expressed in a tissue-dependent 
manner. FXRα is mainly expressed in the liver. FXRα1 and FXRα2 are moderately 
expressed in the ileum and adrenal gland, while FXRα3 and FXRα4 are abundantly 
expressed in the ileum and moderately expressed in the kidney2. The sequence of FXRα1 
has been chosen as the canonical sequence (uniport.org/uniport/Q96R|1). The sequence of 
the FXR-LBD is conserved among all four isoforms. 
 
2.2 FXR as a drug target 
 FXR plays an essential role in regulating systemic energy homeostasis and protecting 
many organs, including the liver and intestine. FXR as a metabolic regulator plays an 
important role in bile acid, lipid, cholesterol, and glucose metabolism and helps inter-organ 
communication, particularly the enterohepatic signaling pathway via bile acids. FXR also 
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plays various roles in the kidney, adipose tissue, pancreas, cardiovascular system, and 
tumorigenesis. Given its broad involvement in metabolism and many organs, the 
deregulation of FXR may lead to metabolic disorders and disease-causing abnormalities of 
specific organs. Such actions make FXR a potential drug target in treating metabolic 
diseases and several liver-related disorders, including nonalcoholic steatohepatitis 
(NASH), primary biliary cholangitis (PBC), diabetes, dyslipidemia, and obesity30,31. Many 
FXR agonists have been developed and are undergoing pre-clinical and clinical trials. For 
example, obeticholic Acid (OCA) is a promising candidate for treating liver and metabolic 
disorders, but it has some safety issues. The U.S. food and drug administration has recently 
approved OCA, and it is in late-stage clinical development for the treatment of NASH. 
Adverse effects include elevated cholesterol levels due to FXR over-activation32-34. This 
suggests that partial FXR activation may be an essential strategy to avoid mechanism-based 
side effects. Promising results have been reported from pre-clinical and a phase 1 clinical 
trial of a partial FXR agonist6. 
 
The effect of FXR modulation might be multifaceted according to tissue specificity and 
disease type, suggesting that FXR agonists must be used with care.  
 
2.3 FXR structure  
FXR shares a classic NR structure, consisting of common functional domains (Fig. 5a), a 
highly variable N-terminal ligand-independent transcriptional activation domain (AF-1), 
followed by a highly conserved core DNA-binding domain (DBD), a C-terminal ligand-
binding domain (LBD) that consists of twelve α-helices (H-1 to H-12), a flexible hinge 
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region which separates LBD from DBD, and a ligand-dependent activation function 
domain (AF-2).  
 
 
Fig. 5: Schematic diagram of FXR. (a) Structural organization of FXR (b) Schematic diagram of 
the four FXRα isoforms. [Figure adapted from Jiang et al., 2021] 29 
 
 
The AF-1 region is highly disordered and can interact with coregulator proteins. The FXR-
DBD interacts with DNA in a base-specific manner which allows it to recognize a specific 
DNA sequence. The DBD is highly conserved and consists of two α-helices (H-1 and H-
2) and two four cysteines/zinc nucleated modules35 (Fig. 6a). FXRα1 and FXRα3 each 
have an insert of four amino acids (MYTG) in the hinge region36 (Fig. 5b). The FXR-LBD 
binds to its cognate ligand and recruits coregulator proteins. FXR-LBD consists of 12 α-
helices that fold into three parallel layers to form an alpha-helical sandwich and contains a 
hydrophobic ligand-binding pocket (LBP) to accommodate its ligands (Fig. 6b). The AF-
2 region is in the LBD and includes H-12. For several nuclear receptors, the AF-2 site is 
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crucial for NR activation by small-molecule ligands. Ligand binding changes the 





Fig. 6: (a) Model structure of FXR-DBD (PDB ID: 1R0O of EcR-DBD is used to represent FXR-
DBD) (b) FXR-LBD/OCA complex (PDB ID: 1OSV), FXR-LBD is in green cyan, OCA is in 
orange, and NCoA peptide is in magenta. [Figure adapted from Jiang et al., 2021] 29 
 
 
2.4 FXR: DNA binding 
FXR regulates gene expression by binding DNA as a monomer or heterodimer with 
RXR38,39. The DNA motifs recognized by FXR-DBD are called FXR response elements 
(FXREs) (Fig. 7). In the heterodimer form with RXR, the coactivator binding site (H-
10/11) undergoes allosteric conformational changes, enhancing the transcriptional activity 
of FXR to bind FXREs40,41. The dimerization mechanism between FXR-DBD and RXR-
DBD is still not clear. Diverse FXREs are localized in promoter, intergenic, and intron 
regions of many genes. The binding of FXR to FXREs leads to various biological functions 




Fig. 7: FXR binds to DNA either as a heterodimer with RXR or as a monomer to regulate the 
expression of various genes. [Figure adapted from Wang et al., 2018] 40 
 
 
2.5 FXR activation: Ligand and coactivator binding 
 
The FXR-LBD contains the ligand-binding pocket (LBP) for ligand binding. The bound 
ligand can adjust LBP volume 43. Crucial polar residues (Arg, His) in the LBP form 
hydrogen bond interactions with ligands to position them into correct orientation, while 
hydrophobic residues (Ile, Phe) form hydrophobic interactions with ligands to stabilize the 
LBD43,44.  Previous studies have suggested a mousetrap model for NR activation in which 
the position of H-12 is different in liganded and unliganded (apo) states. H-12 is separated 
from the core LBD (inactive state) in the apo state, while H-12 moves to a more compact 
structure contacting the core LBD upon agonist binding (active state)9. Later studies revised 
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this mouse trap model of activation. They suggest that H-12 is dynamic and possibly non-
helical in the apostate, and H-12 is only formed and stabilized upon agonist binding.  This 
model suggests that more than a single active conformation of the FXR-LBD exists. Recent 
studies have shown differential effects of FXR agonists on FXR regulated gene expression, 
implying that FXR activation is more complex than the mechanism described by the 
mousetrap model10. These studies indicate that the unliganded FXR-LBD recruit 
corepressor such as nuclear receptor corepressor 1 (NCoR). Agonist binding stabilizes H-
12 secondary structure and/or induces an H-12 conformational favorable to coactivator 
binding. Such agonist-induced changes lead to the recruitment of a coactivator (NCoA) 
and dissociation of the corepressor (Fig. 8). 
 
In contrast, an inverse agonist stabilizes the interaction between the FXR-LBD and the 
corepressor by inducing an inactive state with a disordered H-12. Similar mechanisms have 
also been reported for other NRs like PPARγ14. Finally, there may be more than one AF-2 
and H-12 structure that favors coactivator binding as different FXR ligands lead to different 




Fig. 8: Mousetrap model of FXR-LBD activation; binding of an agonist ligand stabilizes the H-
12, allowing coactivator recruitment. (The model shown is of a different NR (RXR).  [Figure 
adapted from Huang et al., 2010] 46 
 
 
2.6 FXR ligands 
 
We have used commercially available FXR ligands, which have been previously 
characterized in cells and structure-function studies. These ligands include full and partial 
agonists that strongly or mildly enhance coactivator peptide recruitment, antagonists/non-
agonists that keep coactivator peptide recruitment to a basal level. The chemical structure 
of FXR ligands used in this study is shown below (Fig. 9). 
 
Tropifexor: 
Tropifexor is a novel and highly potent nonsteroidal, non-bile acid FXR agonist under 
phase 2 human clinical trial to treat primary biliary cholangitis (PBC) and nonalcoholic 
steatohepatitis (NASH)4,5. 
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XL335:   
In vitro and in vivo optimization results indicate that XL335 is a potent and selective FXR 
agonist; oral administration to mice results in reduced cholesterol and triglycerides47. It is 
currently in phase 1 clinical trial. 
  
GW4064:   
GW4064 is a highly effective and selective nonsteroidal agonist of FXR, repressing the 
significant drug-metabolizing enzyme CYP3A4 expression in human hepatocytes48. 
GW4064 was found to raise HDL cholesterol levels and decrease triglycerides in various 
animal species49. Due to some limitations (solubility, toxicity, and UV stability), it is not 
considered a promising drug candidate. However, it is instead used as a tool compound to 
investigate the physiological functions of FXR50. Many nonsteroidal compounds have been 
made based on the GW4064 structure.  
 
CDCA:  
Chenodeoxycholic Acid (CDCA) is the essential steroidal endogenous bile acid ligand of 
FXR. CDCA bound FXR regulates the bile salt export pump expression, which is crucial 
in protecting liver damage51. Therefore, CDCA is more potent compared to other bile acids. 
 
Fexaramine:  





Ivermectin is a drug approved for nematode and arthropod parasites is a highly selective 
FXR antagonist. Treatment of wild-type mice with ivermectin resulted in lowering serum 
glucose and cholesterol levels. In addition, Ivermectin has shown antidiabetic activity by 
enhancing insulin sensitivity in an FXR-dependent manner13. Ivermectin is safe and well-
tolerated in humans and forms the basis for the design of FXR antagonists for the treatment 
of metabolic diseases.  
 
DY268:  





Fig. 9:  Chemical structure of FXR ligands used in thesis research. [Figure adapted for DY268 is 
from Jiang et al., 2021] 29 
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2.7 Coactivator peptides: Steroid receptor coactivator (SRC) 
 
 
Coactivators are a diverse group of proteins responsible for inducing conformational 
changes in agonist-bound NRs that are essential for NR-mediated transcriptional 
activation. A difference between coactivators and transcription factors is that coactivators 
do not directly bind DNA. Steroid receptor coactivators (SRCs) are one of the most studied 
families of coactivators and are implicated in a wide range of human diseases53. Unlike 
NRs, coactivator proteins appear mostly disordered; however, a short helical motif, termed 
the LXXLL motif53, was identified within several coactivators (including SRCs),54,55, 
which binds to a hydrophobic pocket on the LBD. Several NRs have been co-crystalized 
with their cognate ligand and coactivator regions, including peptides, that contain the 
LXXLL motif within the NR interaction domain of coactivators. These structures reveal 
LXXLL motif binding is stabilized by interactions between the motif and the NR AF-2 
surface region, including bonding between NR residues on H-3 and H-12 and the 
coactivator helix backbone amine and carbonyl groups. The SRCs contain three α-helical 
LXXLL motifs essential for their interaction with NRs. The sequences flanking these 
motifs are essential for NR selectivity56.57. SRCs are the most common coactivator for 
FXR, and most of the cocrystals of FXR are with SRC. The SRC LXXLL motif-containing 
peptides used in this work are fluorescein-labeled, namely SRC1-2 and SRC2-2 (Thermo 
Fisher Scientific). Our data shows that they have the highest affinity for FXR compared to 
other SRC family LXXLL motifs. Table 1 shows these sequences of these peptides with 




Table 1: SRC peptides and their sequences. 
 






3 Results:  
 
 
3.1 FXR purification: 
Due to the low solubility and yield of FXR-LBD, we have fused it with polyhistidine-
tagged Escherichia coli (E.coli) maltose-binding protein (His6-MBP). MBP enhances the 
solubility and improves the yield of its fusion protein partner, while the histidine tag 
facilitates purification by immobilized metal affinity chromatography (IMAC) using a 
nickel column58. Cleaving the MBP tag after IMAC purification using tobacco etch virus 
(TEV) protease digestion significantly decreased the stability and yield of FXR-LBD. At 
the same time, cleavage of the MBP tag did not significantly affect FXR-LBD activity, 
leading us to use MBP tagged FXR-LBD for all the experiments (Fig. 10). IMAC 
purification was followed by Fast protein liquid chromatography (FPLC) size exclusion 
purification. Only those fractions of MBP-FXR were selected from FPLC size-exclusion, 
which had the least amount of impurity. Based on the gel analysis, the major impurity 





Fig. 10: Effect of MBP tag cleavage on FXR-LBD activity: Fluorescence anisotropy experiments 
measure the affinity of the coregulator peptide for FXR LBD in the absence (apo) and presence of 
an equimolar concentration of ligands. SRC2-2 efficacy for (a) MBP-FXR LBD wt (Kd (2.3 μM)) 
(b) MBP cleaved FXR-LBD wt (Kd (3.5 μM)). The data shown represent two technical replicates 
from a single experiment. ** 
 






Fig. 11: SDS page gel of size exclusion purified MBP-FXR. Fractions up to 63 were collected 
for experiments.  
 
 
3.2 The efficacy of different FXR ligands in coregulator peptide recruitment 
 
We investigated the correlation of FXR coregulator binding surface structure with function 
(coactivator LXXLL motif peptide affinity) using FXR ligands of different efficacies in 
steroid receptor coactivator (SRC1-2 and SRC2-2) recruitment in vitro. In this study, we 
used six commercially available FXR ligands, including tropifexor,1 XL33547, and 
GW406448, which were reported to be agonists, CDCA an endogenous agonist51, and 
ivermectin13, which is reported to be an antagonist. We used fluorescence anisotropy (FA) 
to measure dissociation constants between fluoresceine-labeled coactivator peptides and 
FXR. The effect of the ligands mentioned above on FXR affinity for the coactivator peptide 
(SRC 2-2) is shown in (Fig. 12a). An increase in FA indicates increased binding of the 
coactivator peptide. A left shift of the curve indicates that a ligand increases the affinity of 




Fig. 12: Efficacy of FXR ligands: Fluorescence anisotropy experiments measure the affinity of 
the coregulator peptide for FXR LBD in the absence (apo) and presence of an equimolar 
concentration (41μM) of ligands. FXR ligands efficacy for (a) SRC2-2 or (b) SRC1-2 recruitment. 
The data shown represent two technical replicates from a single experiment. 
 
 
The Kd values for coregulators interacting with FXR shown in Table 2 indicate that 
Tropifexor is the most efficacious agonist. At the same time, Xl335 and GW4064 are less 
efficacious (partial agonists), and ivermectin has little effect, acting as an antagonist in this 
assay. A similar experiment using the same set of ligands and a different coactivator 
peptide (SRC 1-2) yielded similar results (Fig. 12b). Previous reports had characterized 
tropifexor, XL335, and GW4064 as agonists. However, our data show that they have 
variable efficacy.  
 
Ivermectin has been reported to enhance the binding of both corepressor and coactivator 
peptides13. However, we found that ivermectin either decreases or has no effect on the 
affinity of FXR for SRC2-2 and SRC1-2 peptides. To examine the effects of ivermectin on 
corepressor peptide affinity, we performed FA of fluoresceine-labeled corepressor peptide 
SMRT ID2 (silencing mediator of retinoid and thyroid receptor, interaction domain 2) to 
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measure dissociation constants between SMRT ID2 and FXR using a known FXR 
antagonist ligand DY 268 as standard (Fig. 13). The Kd value of FXR-DY268 (9 μM) and 
FXR-ivermectin (42 μM) for SMRT ID2 combined with the fact that apo FXR shows no 
binding to SMRT ID2 indicate both ligands increase Ivermectin recruitment of SMRT. 
Along with our data showing reduced or no effect on coactivator binding, these data 
suggest that Ivermectin and DY268 are FXR antagonists and would likely function as 
inverse agonists on FXR target genes in vivo. 
 






Apo 20.5 20 
Tropifexor 1.4 2.7 
XL335 4.3 11.8 
GW4064 3.4 8.5 
CDCA 20.7 29.3 
Fexaramine 7.3 20.7 








Fig. 13: Efficacy of antagonists (Ivermectin and DY268) of FXR in corepressor peptide (SMRT 
ID2) recruitment. The data shown represent the standard deviation from two technical replicates 




3.3 H-12 conformational change observed by 19-F NMR 
19-F NMR is a sensitive tool to observe structural changes59. We used 19F-NMR to observe 
the effect of ligands on H-12 dynamics. For these 19F NMR studies, a cysteine in MBP-
FXR is covalently labeled (linked) with 3-Bromo-1,1,1-trifluoroacetate (BTFA), 
containing a trifluoromethyl (-CF3) group, the source of the fluorine signal. As the CF3 
group rotates rapidly, this group produces a single NMR peak. Since MBP does not have 
any native cysteines while FXR LBD has three, BTFA labeling affects only the FXR LBD.   
 
Wild-type FXR LBD contains three native cysteines on H-9 (C419), H-10 (C432), and H-
12 (C466).  The side chains of C432 and C466 appear to be solvent-exposed in a crystal 
structure of the FXR LBD (PDB ID: 3DCT); hence, they are most likely to be labeled with 
BTFA; in contrast, C419 is inside a hydrophobic pocket and is, therefore, less likely to get 
labeled (Fig. 14). We first determined which peaks arise from each of the three labeled 
cysteines by making receptors with a single mutation (C432H or C466S) and a double 
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mutant (DM) incorporating both these mutations. We replaced these cysteines with 
histidine and serine, respectively, because they are identical to the corresponding residues 
in murine FXR. A deconvoluted spectrum of FXR-LBD wt (2x BTFA post-label) bound 
to ivermectin shows a broad and a sharp peak (Fig. 15a) while C432H and C466S shows 
one broad and sharp peak, respectively indicating the source of each peak (Fig. 15b,c). 
Spectra of the double mutant show a well-separated, very weak, and ligand-responsive 
signal from the third cysteine (C419), indicating minimal exposure and labeling of this 
cysteine (Fig. 16b). In addition, the DM spectra show a larger signal that does not change 
upon ligand binding, which likely originates from labeled co-purifying proteins. We 
analyzed difference spectra where DM spectra are subtracted from C432H or C466S 
spectra to eliminate these unchanging signals. 
 
C432H-DM difference spectra mutants (with DM spectra scaled down to 0.58 to avoid 
negative peaks) shows broad peaks for apo and ivermectin. Peak broadening indicates that 
H-12 is dynamic,60 switching between multiple conformations on the microsecond to 
millisecond timescale in the absence of ligand (apo) and when bound to an antagonist (Fig. 
16a). The binding of Tropifexor, the most efficacious agonist, results in a narrower, more 
consolidated spectrum. These NMR results indicate that H-12 dynamics correlate with an 
affinity for coactivators. Antagonist ligands and apo generate broad H-12 peaks, while 
efficacious agonists induce narrow H-12 NMR peaks consistent with a stable and 
structured H-12.    
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Fig. 15: Mutations in FXR-LBD bound to ivermectin to verify the source of peaks in 19F-NMR. 
Deconvoluted spectra of (a) FXR-LBD wt (b) C432H (c) C466S. peak on the rightmost side (*) is 






Fig. 16: 19-F NMR result of C432H and Double Mutant (C432H, C466S) MBP-FXR LBD-BTFA 




We deconvoluted the difference spectra using our previously published method60 to aid in 
spectral interpretation. The multiple peaks in the deconvoluted spectra indicate multiple 
FXR conformations, and the signal area of each peak indicates the relative population of 
each particular FXR conformation. For example, the deconvolution of C432H-DM 
difference spectra indicates a broad peak for apo and ivermectin bound FXR and sharper 
peaks for the partial and full agonists (Fig. 17). A list of major peaks in each spectrum and 

























Table 3: List of the significant peak, size, and percentage of each spectrum in Fig. 16  
 
















































 FA data shows that DY268 increases FXR affinity for a corepressor peptide (SMRT ID2) 
more than ivermectin. The FXR ivermectin complex with or without co-bound SMRT ID2 
shows broad shifted peaks indicating considerable H-12 dynamics even after SMRT is 
recruited to this complex (Fig. 18). In contrast, DY268, the most efficacious in SMRT 
recruitment, induces an FXR 19F NMR spectrum with a much narrower peak (42 Hz), 
suggesting H-12 is relatively stable when bound to DY268. The addition of SMRT ID2 
leads to a slightly broader and right-shifted peak (54 Hz), indicating slightly increased H-
12 dynamics when SMRT is recruited (Fig. 18).       
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Fig. 18: C432H-DM difference spectrum of MBP-FXR-LBD-BTFA (pre-labeled) apo protein and 
bound to Ivermectin, DY268 and added SMRT ID2 corepressor. DM spectra were scaled down to 
0.701 to avoid negative peaks. NOTE: Elizabeth Sather purified the protein and prepared and sent 
samples for NMR analysis for the spectra displayed in this figure. 
 
 
Because H-12 contacts coactivators in published crystal structures, the addition of SRC1-
2 coactivator peptide is expected to affect H-12 19F-spectra, as expected, the addition of 
SRC1-2 consolidates the two H-12 signals in FXR-agonist complexes (Fig. 19). This result 
is consistent with our previous work in PPARγ, where the addition of coactivators to 




Fig. 19: Addition of a peptide, SRC1-2 changes the H-12 spectra and consolidates the two H-12 
signals in FXR-agonist complexes. The deconvoluted spectrum of (a) FXR C432H bound to 
tropifexor (b) FXR C432H bound to tropifexor and peptide SRC1-2. ** 
 
 
Cleaving the MBP tag has no significant impact on the NMR signal from FXR LBD (Fig. 
20), consistent with the anisotropy data that showed little impact of cleavage on FRX 
affinity for coactivators (Fig. 10). The process of cleaving the MBP increases purity (as 
determined by Coomassie stained gel, data not shown), therefore this impurity peak is 




Fig. 20: Cleaving the MBP tag does not affect the 19F NMR signal. The deconvoluted spectrum 
of (a) FXR-MBP wt bound to tropifexor (b) FXR without MBP tag bound to tropifexor. The 
rightmost peak (*) in (a) is likely from impurity similar as explained in figure 15. ** 
 
 
3.4 Simulation confirms the 19F-NMR results 
 
Helix 12 19F-NMR shows broad apo and ivermectin bound wild-type FXR signals, 
indicating a dynamic H-12. In contrast, FXR bound to the partial agonists XL335, 
GW4064, and especially the most efficacious agonist Tropifexor show narrower, more 
consolidated spectra indicative of less H-12 conformational heterogeneity. We ran 
conventional MD (cMD) simulations of apo and ligand-bound FXR to define better the 
structures and dynamics indicated by the 19F NMR spectra. Simulation models were built 
using the PDB crystal structure of FXR LBD bound to respective ligands in which H-12 is 






Table 4: cMD builds and their corresponding PDB files. 
 






Tropifexor + SRC2-3 7D42 
 
 
We ran six replicates of each simulation for a sufficiently long time to yield fairly 
consistent H-12 RMSD (average deviation over the sequence PLLCEI of H-12) relative to 
the starting structure (Fig. 21). The simulation for FXR bound to tropifexor and tropifexor 
with peptide SRC2-3 was in progress when this thesis was written and will be stopped and 





Fig. 21: MD simulations of wt FXR-LBD apo and bound to different ligands. Here we observe 
the convergence of H-12 RMSD relative to starting structure. The size of each frame is 10 ns. 
 
 
Six independent simulations (approx. 100 μs each) of Apo FXR LBD indicate H-12 
exchanges between many conformations distinct from the starting crystal structure (Fig. 
22a). This result is consistent with the broad peak observed in 19F-NMR for apo FXR-
LBD, indicating exchange between different H-12 conformations.  
 
We built the ivermectin model from the only ivermectin-containing crystal structure 
available (4WVD). Because H-12 is not resolved in 4wvd, part of H-12 was added to 4wvd 
from another FXR crystal structure (3DCT) in Chimera. Six independent simulations 
(approx. 60 μs each) indicate that H-12 exchanges between distinct conformations when 
bound to ivermectin (Fig. 22c). These results are consistent with the 19F-NMR, which 
36 
shows a broad peak indicating conformational exchange of H-12 when bound to 
ivermectin.   
 
Models for partial agonist XL335 and GW4064 bound FXR LBD were built using their 
crystal structures, 3FLI, and 3DCT, respectively. Six independent simulations (each 
XL335 simulation ran for approximately 100 μs while each GW4064 simulation ran for 
approximately 90 μs) indicate that partial agonist binding leads to primarily one major low 
energy conformation, H-12, which resembles the starting active H-12 conformation (Fig. 
22 b,d). This result is consistent with the 19F-NMR result, where the XL335 and GW4064 
produce single H-12, whereas apo FXR H-12 exchanges between two peaks. 
 
The simulation model for full agonist Tropifexor was built using its crystal structure 7D42. 
7D42 includes a bound coactivator (SRC2-3), which we removed for these simulations. 
Six independent simulations (each run for approx. 50 μs) indicate that H-12 occupies 
almost exclusively one major low energy conformation (Fig. 22e) similar to the starting 
active conformation in the crystal structure. This result is consistent with the 19F-NMR, 
where tropifexor induces the narrowest, most consolidated H-12 19F-NMR peak. These 
data indicate that the most efficacious agonist (tropifexor) is the most efficacious at 
stabilizing H-12. Likewise, the partial agonists provide both intermediate coactivator 
recruitment efficacy and stabilization of H-12.  
 
We surmised that the addition of a coactivator would further stabilize H-12 in the FXR-
tropifexor complex via interaction between H-12 and the coactivator. To verify this via 
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simulation, we built a simulation model of FXR bound to Tropifexor and a coactivator 
peptide SRC2-3 [KKKENALLRYLLDKDDTKD] using crystal structure 7D42 (which 
includes the co-bound SRC2-3). We ran six independent simulations (approx. 40 μs each) 
and found that H-12 shows one sharp major low energy conformation (Fig. 22f), indicating 
that the binding of a coactivator may further stabilize H-12. 
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Fig. 22: Histogram of H-12 RMSD. The sum of RMSD frequencies for all the six independent 
runs for H-12 indicates the RMSD of most conformations. RMSD close to zero indicates 
conformations similar to starting crystal structure. FXR bound to (a) apo (b) Xl335 (c) Ivermectin 
(d) GW4064 (e) Tropifexor (f) Tropifexor and coactivator SRC2-3.    
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Observation of the RMSD fluctuation of ligands in the above simulations indicates that 
agonists stay primarily in one conformation. In contrast, antagonist conformation fluctuates 





Fig. 23: RMSD fluctuations of ligand bound to LBP of FXR-LBD. (a) Ivermectin (b) XL335 (c) 








FXR is a ligand-activated nuclear receptor that recruits coactivators upon binding agonists. 
The FXR conformational changes that result in increased affinity for coactivators are 
unclear. Our data suggest that conformational changes of H-12 are mainly responsible for 
FXR activity and coactivator recruitment; however, given that two partial agonists induce 
distinct H-12 structure and similar coactivator affinity, there are likely other structural 
aspects important to coactivator affinity.  
 
Our data also suggest that the binding of ligands of different efficacies leads to different 
H-12 conformational ensembles. 19F-NMR and simulation data indicate that H-12 
exchanges between multiple conformations on the microsecond to millisecond timescale 
for apo-FXR and in the presence of an antagonist (Ivermectin). In contrast, another 
antagonist/inverse agonist that induces the highest affinity for a corepressor peptide 
(DY268) induces mainly one H-12 conformation with a distinct chemical shift and likely 
distinct conformation from agonist bound FXR. There is currently no crystal structure 
available for FXR bound to DY268, so we could not perform a simulation of this complex. 
The binding of partial agonists, and to a larger degree, binding of a full agonist, stabilizes 
H-12 into a structurally active state which favors coactivator recruitment. 19F-NMR data 
clearly shows the most stabilization of H-12 (C432H mutant) by the most efficacious 
agonist (tropifexor) and inverse agonist (DY268) indicated by the sharp peaks. These data 
show a correlation between ligand efficacy and H-12 conformation. 
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Long-run simulation data are consistent with the 19F-NMR results. All simulations were 
started from FXR crystal structures with H-12 in the same active conformation. Simulation 
of Apo-FXR and Ivermectin-bound FXR results in various H-12 conformations different 
from the starting structure; such heterogeneity is expected to be conducive to forming a 
key hydrogen bond between the coactivator backbone and the H-12 charge clamp residue 
(E467)31  or hydrophobic contact between H-12 and the coactivator. The simulation is 
consistent with 19F-NMR, where we see a broad peak of H-12 indicating μs to ms lifetime 
conformational exchange. Simulations of FXR bound to partial and strong agonists show 
that H-12 maintains a conformation similar to the starting PDB active structure [For the 
full agonist, Tropifexor, H-12 shows less variance from the starting structure than the 
partial agonists (XL335 and GW4064)]. The binding of agonists consolidates FXR LBD 
into a structurally active state that favors coactivator binding.  
 
Interestingly the two partial agonists induce similar efficacy of coactivator recruitment but 
distinct H-12 conformational ensembles. This observation leaves open the possibility that 




FXR plays a crucial role in protecting the liver and other organs via the regulation of bile 
acid and is crucial for regulating other metabolic processes, making FXR a potential 
therapeutic target for treating several liver-related disorders. The FXR-LBD shows 
multiple low-energy conformational states of the AF-2 coregulator binding surface. Upon 
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efficacious ligand binding, some of these states are favored, indicating that activation of 
FXR is more complex than a simple mousetrap model consisting of two well-defined states. 
Fluorescence anisotropy, solution 19F-NMR, and molecular dynamics data indicate that 
H-12 conformational changes are mainly responsible for FXR activity and coregulator 
recruitment which clarifies the structural model of FXR activation. We also found 
structural evidence that efficacious inverse agonists stabilize a distinct H-12 structure from 
efficacious agonists. Furthermore, H-12 exchanges between multiple conformations in 
Apo FXR and FXR bound to less efficacious agonists. This further defines the structural 
basis for graded agonism in FXR.   
 
3.7 Future Directions 
 
The two partial agonists, Xl335 and GW4064, induce distinct H-12 conformations as 
shown by solution 19F-NMR and molecular dynamics simulation but have similar 
coactivator affinity as shown by fluorescence data. These data indicate that there are likely 
other structural aspects important to coactivator affinity.  
 
Regions apart from the AF-2 region, including H-11 can indirectly impact H-12 
stabilization. In addition, the H-3 RMSD determined from molecular dynamics simulation 
data indicates that the binding of an agonist restricts the conformation of H-3 compared to 
apo and antagonist bound FXR (Fig. 24). 
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Fig. 24: H-3 RMSD of FXR when bound to different ligands. (a) apo (b) XL335 (c) Ivermectin 
(d) GW4064 (e) Tropifexor (f) Tropifexor + SRC2-3. 
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The simulation data can be verified using solution 19F-NMR by inserting a cysteine on H-
3, as shown in Figure 25. To observe which region of H-3 shows the largest changes in 
conformation, we could make three individual cysteine mutations in the solvent-exposed 
residues (Fig. 25). This can give us insight into any correlation between H-3 stabilization 




Fig. 25: Position of residues on H-3 for possible single cysteine mutations to observe H-3 














The protocol of the methods used in this work is very much similar to one of our labs' 
previous published work14. 
 
4.1 Protein purification 
 
 A pDEST-566 plasmid [pDest-566 was a gift from Dominic Esposito (Addgene plasmid 
#11517; http://n2t.net/addgene:11517; RRID: Addgene_11517)] carrying the gene for 
ampicillin resistance and N-terminally 6xHis-MBP tagged FXR containing a tobacco etch 
virus (TEV) nuclear inclusion protease recognition site between the MBP tag and protein 
[6xHis-MBP-TEV-FXR] of interest was transformed into chemically competent E.coli 
BL21 (DE3) Gold cells. Cells were grown in either terrific broth (TB) or Luria broth (LB). 
Cells grown in TB media at 37 °C were induced at an OD600 of 0.6-0.8 by adding 0.5 mM 
isopropyl β-D-1-thiogalactopyranoside (IPTG), and the temperature was lowered to 18 °C. 
Induction proceeded for 16-18 h before harvesting. Harvested cells were homogenized into 
20 mM Tris-base (pH 7.5), 500 mM NaCl, 5 mM tris(2-carboxyethyl) phosphine (TCEP), 
10% glycerol, 20 mM imidazole and lysed using a C-5 Emulsiflex high-pressure 
homogenizer (Avestin). Lysates were then clarified  (centrifugation at 19,000 g for 45 
minutes and filtered through a 0.45 μm filter) and passed through two Histrap FF 5 ml 
columns in series (GE Healthcare) overnight at a flow rate of 1 ml/min using an AKTA 
start (GE Healthcare). Protein was eluted using a gradient from 20 to 250 mM imidazole. 
Fast protein liquid chromatography was performed on AKTA start (GE Healthcare). The 
eluted 6xHis-MBP FXR was further purified by size exclusion chromatography (SEC) gel 
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filtration using HiLoad Superdex 75 (GE Healthcare). SEC was performed in 50 mM Tris-
base (PH 8.3), 500 mM NaCl, 10 mM TCEP, 10% glycerol buffer. Protein purity was 
determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
analysis (Bio-Rad).   
 
4.2 FXR-LBD sequence used in this work: 246-472 
 
T P D Q Q T L L H F I M D S Y N K Q R M P Q E I T N K I L K E E F S A E E N F L I 
L T E M A T N H V Q V L V E F T K K L P G F Q T L D H E D Q I A L L K G S A V 
E A M F L R S A E I F N K K L P S G H S D L L E E R I R N S G I S D E Y I T P M F 
S F Y K S I G E L K M T Q E E Y A L L T A I V I L S P D R Q Y I K D R E A V E K L 
Q E P L L D V L Q K L C K I H Q P E N P Q H F A C L L G R L T E L R T F N H H H 
A E M L M S W R V N D H K F T P L L C E I W D V Q  
 
 
4.3 Site-directed mutagenesis 
 
Mutations in FXR LBD were generated using the Quickchange II site-directed mutagenesis 
kit (Agilent) using primers listed in Table 5. The presence of the expected mutation and 
absence of spurious mutations was confirmed by Sanger sequencing (Eurofins). 
 






C432H 5’ -caggcgacccaggagatgggcaaagtgttgagga-3’ 
C466S 5’ -cgtcccagatttcagagagaagtggggtaaactt-3’ 
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4.4 Fluorescence anisotropy (FA) assay 
 
FA peptide binding assay was performed by plating a mixture of 50 nM peptide with an N-
terminal FITC tag, 12-point serial dilutions (1:2) of MBP-FXR LBD wt, and FXR ligands 
from approx. 50 μM to 24 nM. FXR-LBD and FXR ligands were added at a 1:1 ratio. This 
mixture was added to wells of low-volume 384-well black plates (Grenier Bio-one, catalog 
number 784076) to a final volume of 16 μl. Peptides were purchased from ThermoFisher 
(Waltham, MA, USA) for SRC1-2 peptide, sequence: LTERHKILHRLLQEGSPSD (19); 
SRC2-2 peptide, sequence: LKEKHKILHRLLQDSSSPV (19). All dilutions were made in 
SEC buffer (pH 8.3), 0.01% fatty-acid-free bovine albumin (BSA) (EMD Millipore, 
catalog number 126575), 0.01% Tween. Assay titrations were performed in duplicate. 
Plates were incubated in the dark at room temperature for 2 hours before being read by a 
Synergy H1 microplate reader (BioTek). FA was measured by excitation at 485 nm/20 nm 
and emission at 528 nm/20 nm for FITC/5-FAM. Data were fit using nonlinear regression 
(agonist vs. response-variable slope 4 parameters) in Prism 9.0.0.    
 
Some of the previous samples for fluorescence anisotropy were prepared using 20 mM 
Tris-base, 150 mM NaCl, 25 mM imidazole, and 10% glycerol at pH 8.0. ** Samples were 
prepared by this method in Figure 10. 
 
4.5 Preparation of 19F-NMR samples  
19F-NMR samples were prepared to a final concentration of 41 μM protein in 520 ul 
volume containing 10% D2O. The addition of ligand was done in two separate injections 
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of the compound to reduce precipitation. Injections were spaced 20-30 min apart to allow 
time for binding. All ligands were dissolved in D6-dimethylsulfoxide (DMSO). Deuterated 
solvents were obtained from Cambridge Isotope Laboratories Inc. and were at least 99% 
isotopically pure. The final concentrations of ligand for all samples were 1x ligand to the 
protein. FXR mutant proteins were purified by first lysing E.coli cells and then went 
through centrifugation at 19,000 g for 1 h, then labeled with 0.1% BTFA (9.63 M stock) 
added to the lysate, incubated at 4 °C for 15-20 minutes, then filtered using a 0.45 μm filter 
before IMAC His-tag purification. NMR samples were prepared by buffer exchanging 
protein samples >100x into 50 mM NaCl, 50 mM Tris-base, 10mM TCEP, 10% glycerol 
(pH 8.3) using 30 kD MWCO Amicon Ultra-15 concentrators (Merck Millipore) to remove 
excess NaCl. After the ligands were added in a 1:1 ratio in two steps at an interval of 15-
20 min to avoid ligand precipitation, followed by the addition of buffered D2O. 
 
Some previous 19F-NMR samples were prepared using different buffer conditions and 
labeling. MBP-FXR LBD purified in 20  mM Tris base, 150 mM NaCl, 25 mM imidazole 
and 10% glycerol at pH 8.0. 2X BTFA was labeled after purification and incubated at 4C 
overnight. Samples were buffer exchanged in 25mM MOPS, 25mM KCl and 1mM EDTA 
>100x. The rest of the methods were the same as explained earlier. **Samples were 






4.6 Molecular dynamics simulation   
 
Missing residues in the crystal structure compared to our FXR LBD construct used in NMR 
were added using the modeler in Chimera software, and a PDB file was saved. This PDB 
file was then submitted to the h++ server (http://biophysics.cs.vt.edu/H++) to determine 
the state of titratable protons at pH 7.4 along with more realistic rotamers for some residues. 
This h++ PDB file was then given AMBER residue names using pdb4amber 
(AmberTools14). The ligand from this PDB file was removed, and hydrogens were added 
in Chimera then submitted to the RED server for RESP charge assignment. The output 
mol2 file was then used to prepare a gaff2 file and a force modification file (frcmod). Tleap 
was then used to generate parameter and coordinate files using ff14SB and GAFF2 values. 
A truncated octahedron solvation cell with boundaries at least 10 Å from any protein atom 
was built with TIP3P water. The system was neutralized with Na+ ions, and K+ and Cl- ions 
were added to 0.5 M. Joung and Cheatham ion parameters were used. Minimization (imin 
= 1) and equilibration were carried out in nine steps with non-bonded cutoff set to 8 Å and 
with the equilibrations carried out at 310 K. The final restart file from this process was 
used along with a hydrogen mass repartitioned parameter file (modified using parmed) to 
run new simulations with new randomized atomic velocities using 4 fs steps at 310 K. 
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